Sanofi (EPA:SAN) has been given a €75.00 ($87.21) price objective by stock analysts at Jefferies Financial Group in a note issued to investors on Friday. The brokerage presently has a “neutral” rating on the stock. Jefferies Financial Group’s target price would suggest a potential upside of 13.34% from the company’s previous close.
Several other research analysts also recently issued reports on the stock. BNP Paribas set a €87.00 ($101.16) target price on shares of Sanofi and gave the stock a “buy” rating in a research note on Tuesday, September 11th. Deutsche Bank set a €87.00 ($101.16) target price on shares of Sanofi and gave the stock a “buy” rating in a research note on Thursday, September 6th. Bank of America set a €95.00 ($110.47) target price on shares of Sanofi and gave the stock a “buy” rating in a research note on Monday, September 10th. Goldman Sachs Group set a €74.00 ($86.05) price objective on shares of Sanofi and gave the company a “neutral” rating in a research report on Thursday, June 14th. Finally, Citigroup set a €93.00 ($108.14) price objective on shares of Sanofi and gave the company a “buy” rating in a research report on Friday, August 10th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating to the stock. Sanofi currently has a consensus rating of “Hold” and an average price target of €79.16 ($92.04).
Shares of EPA SAN opened at €66.17 ($76.94) on Friday. Sanofi has a 52-week low of €63.09 ($73.36) and a 52-week high of €92.97 ($108.10).
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
See Also: What is a stock buyback?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.